NO974123D0 - Conjugate of protein and lipid consisting of heparin-binding protein (HBP) and a ceramide analogue, and its pharmaceutical use in the treatment of conditions that cause stress damage to cells - Google Patents

Conjugate of protein and lipid consisting of heparin-binding protein (HBP) and a ceramide analogue, and its pharmaceutical use in the treatment of conditions that cause stress damage to cells

Info

Publication number
NO974123D0
NO974123D0 NO974123A NO974123A NO974123D0 NO 974123 D0 NO974123 D0 NO 974123D0 NO 974123 A NO974123 A NO 974123A NO 974123 A NO974123 A NO 974123A NO 974123 D0 NO974123 D0 NO 974123D0
Authority
NO
Norway
Prior art keywords
protein
hbp
heparin
conjugate
cells
Prior art date
Application number
NO974123A
Other languages
Norwegian (no)
Other versions
NO974123L (en
Inventor
Hans Florgaard
Poul Baad Rasmussen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO974123D0 publication Critical patent/NO974123D0/en
Publication of NO974123L publication Critical patent/NO974123L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
NO974123A 1995-03-09 1997-09-08 Conjugate of protein and lipid consisting of heparin-binding protein (HBP) and a ceramide analogue, and its pharmaceutical use in the treatment of conditions that cause stress damage to cells NO974123L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK24095 1995-03-09
PCT/DK1996/000099 WO1996028544A1 (en) 1995-03-09 1996-03-11 A protein-lipid conjugate, consisting of heparin binding protein (hbp) and a ceramide analogue, and its pharmaceutical use in treatment of conditions involving stress injury to cells

Publications (2)

Publication Number Publication Date
NO974123D0 true NO974123D0 (en) 1997-09-08
NO974123L NO974123L (en) 1997-11-07

Family

ID=8091326

Family Applications (1)

Application Number Title Priority Date Filing Date
NO974123A NO974123L (en) 1995-03-09 1997-09-08 Conjugate of protein and lipid consisting of heparin-binding protein (HBP) and a ceramide analogue, and its pharmaceutical use in the treatment of conditions that cause stress damage to cells

Country Status (7)

Country Link
EP (1) EP0871721A1 (en)
JP (1) JPH11501636A (en)
CN (1) CN1099462C (en)
AU (1) AU716791B2 (en)
CA (1) CA2214799A1 (en)
NO (1) NO974123L (en)
WO (1) WO1996028544A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1032412A1 (en) * 1997-11-20 2000-09-06 Novo Nordisk A/S Use of heparin-binding protein for the modulation or prophylaxis of apoptosis of mammalian cells
CN1550235A (en) * 1999-04-29 2004-12-01 ŵ��Ų�ڿ˹�˾ Use of heparin-binding antagonists in the inhibition of bradykinin release
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7772196B2 (en) 2000-01-10 2010-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
JP4782966B2 (en) * 2000-01-10 2011-09-28 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド Use of lipid conjugates in the treatment of disease
US7393938B2 (en) 2000-01-10 2008-07-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7893226B2 (en) 2004-09-29 2011-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US7141552B2 (en) 2000-01-10 2006-11-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7608598B2 (en) 2000-01-10 2009-10-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of conjunctivitis
US7101859B2 (en) 2000-01-10 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases
US7811999B2 (en) 2000-01-10 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Use of lipid conjugates in the treatment of diseases
US9040078B2 (en) 2000-01-10 2015-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases of the nervous system
US8076312B2 (en) 2000-01-10 2011-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Use of lipid conjugates in the treatment of disease
US8916539B2 (en) 2000-01-10 2014-12-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of disease
US8501701B2 (en) 2000-01-10 2013-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of lipid conjugates in the treatment of disease
US8304395B2 (en) 2000-01-10 2012-11-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Lipid conjugates in the treatment of disease
US20060189570A1 (en) 2000-01-10 2006-08-24 Saul Yedgar Use of lipid conjugates in the treatment of infection
US8883761B2 (en) 2001-01-10 2014-11-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of lipid conjugates in the treatment of diseases associated with vasculature
GB0521276D0 (en) * 2005-10-19 2005-11-30 Lewitt Moira S Medical uses and therapies based upon the action of azurocidin on IGFBP-1
WO2010132402A1 (en) 2009-05-11 2010-11-18 Morria Biopharmaceuticals, Inc Lipid-polymer conjugates, their preparation and uses thereof
US8859524B2 (en) 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
US8906882B2 (en) 2005-11-17 2014-12-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of allergic rhinitis
CA2705785A1 (en) 2006-11-14 2008-05-22 Saul Yedgar Use of lipid conjugates in the treatment of diseases or disorders of the eye
CN110726846B (en) * 2019-12-04 2022-08-26 南京市儿童医院 Application of HBP protein as diagnostic marker of Kawasaki disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2846385B2 (en) * 1988-03-17 1999-01-13 ノボ・ノルデイスク エー／エス Heparin binding proteins, DNAs encoding them, methods for their production and therapeutic preparations containing them
WO1991000907A1 (en) * 1989-07-05 1991-01-24 Emory University Monocyte chemotactic proteins and related peptides
US5484885A (en) * 1989-07-05 1996-01-16 Emory University Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37

Also Published As

Publication number Publication date
AU716791B2 (en) 2000-03-09
CA2214799A1 (en) 1996-09-19
NO974123L (en) 1997-11-07
CN1099462C (en) 2003-01-22
EP0871721A1 (en) 1998-10-21
WO1996028544A1 (en) 1996-09-19
JPH11501636A (en) 1999-02-09
AU4784896A (en) 1996-10-02
CN1181783A (en) 1998-05-13

Similar Documents

Publication Publication Date Title
NO974123L (en) Conjugate of protein and lipid consisting of heparin-binding protein (HBP) and a ceramide analogue, and its pharmaceutical use in the treatment of conditions that cause stress damage to cells
NO2009028I1 (en) Kinazoline derivatives, their use and preparation, and pharmaceutical preparations
NO306253B1 (en) Arylsulfonyl hydroxamic acid derivatives, their use and pharmaceutical preparation
DK0826673T3 (en) Acetamide derivatives, processes for their preparation and medical preparations
EP0713530A4 (en) High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins
DK0871656T3 (en) Dolastatin derivatives, their preparation and use
NO951447D0 (en) Organoalumino product, preparation and use
NO20003119L (en) Aminobiguanides for disinfecting contact lenses and preserving pharmaceutical preparations
NO963344D0 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes and their use
BR9600145A (en) Process for obtaining a flavana-lignan preparation composed of flavano-lignan medicine and process for its preparation
IL117989A (en) N-(1-(3,5-bisfluoromethylbenzoyl)-2- benzyl-piperidin-4-YL)-4-oxo-4H-1- benzopyran-2 carboxamides their preparation and pharmaceutical compositions comprising them
BR9505962A (en) Aqueous pharmaceutical suspension and process for its preparation
NO975076D0 (en) Pharmaceutical preparation containing thiagabine hydrochloride and process for its preparation
BR9600778A (en) Benzenesulfonylurea and - thiouréla replaced process for its preparation, use and medicine
IT8922547A0 (en) BOX, PARTICULARLY FOR MEDICINES, AND PROCEDURE FOR ITS MANUFACTURING
BR9811483B1 (en) Amino-ethyl-phenoxy acetic acid derivatives and pain relieving drugs and promoting the removal of calculi in urolithiasis.
DE69513830D1 (en) Blood pressure monitor in modular design
NO973980D0 (en) Imiadazole derivatives and medical preparations
FI960587A (en) Substituted benzenesulfonylureas and thioureas, process for their preparation and their use in the manufacture of a pharmaceutical preparation, and pharmaceutical preparations containing them
PT1100775E (en) BENZENOSULFONILUREIAS Y BENZENOSULFONILTIUREIAS 2,5-SUBSTITUTES PROCESS FOR THE PREPARATION OF THEIR USE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
PT1228031E (en) MODIFIED 15-HYDROXYETHYTETRAENOIC ACID DERIVATIVES IN THE OMEGA CHAIN AND ITS USE IN THE TREATMENT OF OCULAR SECURA
NO980471D0 (en) Benzenesulfonamide derivatives, their preparation and therapeutic uses thereof
BR9500068A (en) Packaging and method for its preparation
NO890965D0 (en) SUPER LEADING PRODUCT AND PROCEDURE FOR ITS MANUFACTURING.
NO974932D0 (en) Pesticide preparations and process for their preparation